• 1
    Kohn LT, Corrigan JM, Donaldson MS, eds. To err Is human: Building a safer health system. Washington DC, National Academy Press, 1999.
  • 2
    Expert Group on Learning from Adverse Events in the NHS. An organisation with a memory. London, Stationery Office, 2000.
  • 3
    Australian Council for Safety and Quality in Healthcare. Second national report on patient safety: improving medication safety. Canberra, Australian Council for Safety and Quality in Healthcare, 2002.
  • 4
    Rosholm JU, Bjerrum Hallas J, Worm J, Gram LF. Polypharmacy and the risk of drug–drug interactions among Danish elderly. Danish Med Bull 1998; 42: 2103.
  • 5
    Pirmohamed M, James S, Meakin S, Green C, Scott A, Walley T, Farrar K, Park B, Breckenridge A. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ 2004; 329: 159.
  • 6
    Shojania KG, Duncan BW, McDonald KM, Wachter RM, eds. Critical analysis of patient safety practices. Evidence Report/Technology Assessment No. 43. AHRQ Publication No. 01-E058. Rockville, MD, Agency for Healthcare Research and Quality, 2001.
  • 7
    Hazlet TK, Lee TA, Hansten P, Horn J. Performance of community pharmacy drug interaction software. J Am Pharm Assoc 2001; 41: 2004.
  • 8
    Mukasa D, Hughes, J. Drug interactions in the elderly: frequency, significance and differences among standard reference resources. Australian Pharmacist 2002; 21: 6038.
  • 9
    Chen YF, Neil KE, Avery AJ, Dewey ME. Prescriptions with potentially hazardous/contraindicated drug combinations presented to community pharmacies. Int J Pharm Pract 2002; 10(Suppl): R29.
  • 10
    Joint Formulary Committee. British National Formulary, 46th edn. London, British Medical Association and Royal Pharmaceutical Society of Great Britain, 2003.
  • 11
    Vidal. Interactions medicamenteuses. Paris, Vidal, 2003.
  • 12
    Tatro D, ed. Drug interaction facts. Facts and Comparisons. Wolters Kluwer, St Louis. MO: 2003.
  • 13
    Klasko RK, ed. Drug-Reax system [database on CD-ROM]. Greenwood Village, Thomson Micromedex, 2003.
  • 14
    Fulda TR, Valuck RJ, Vander Zanden J, Parker S, Byrns PJ. Disagreement among drug compendia on inclusion and ratings of drug–drug interactions. Curr Ther Res 2000; 61: 5408.
  • 15
    Chao S, Maibach, H. Lack of drug interaction conformity in commonly used drug compendia for selected at-risk dermatologic drugs. Am J Clin Dermatol 2005; 6: 10511.
  • 16
    Abarca J, Malone D, Armstrong E, Grizzle AJ, Hansten PD, Van Bergen RC, Lipton RB. Concordance of severity ratings provided in four drug interaction compendia. J Am Pharm Assoc 2004; 44: 13641.
  • 17
    Aronson JK. Drug interactions–information, education, and the Brtish National Formulary. Br J Clin Pharmacol 2004; 57: 3712.
  • 18
    Stockley IH. Drug Interactions, 6th edn. London, The Pharmaceutical Press, 2006.
  • 19
    Saito M, Hirata-Koizumi M, Miyake S, Hasegawa R. Comparison of information on the pharmacokinetic interactions of Ca antagonists in the package inserts from three countries (Japan, USA and UK). Eur J Clin Pharmacol 2005; 61: 5316.
  • 20
    Bergk V, Haefeli W, Gasse C. Information deficits in the summary of product characteristics preclude an optimal management of drug interactions: a comparison with evidence from the literature. Eur J Clin Pharmacol 2000; 61: 32735.
  • 21
    Hansten PD, Horn JR, Hazlet TK. ORCA: Operational classification of drug interactions. J Am Pharm Assoc 2001; 41: 1615.
  • 22
    Malone DC, Abarca J, Hansten, PD, Grizzle AJ, Armstrong EP, Van Bergen RC, Duncan-Edgar BS, Solomon SL, Lipton RB. Identification of serious drug–drug interactions: results of the partnership to prevent drug–drug interactions. J Am Pharm Assoc 2004; 44: 14251.
  • 23
    Juurlink DN. Drug–drug interactions: where do we go from here? J Am Pharm Assoc 2004; 44: 12834.